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A New Curcumin Derivative, HBC, Interferes with
the Cell Cycle Progression of Colon Cancer Cells
via Antagonization of the Ca2/Calmodulin Function
rivatives and evaluated their biological activities [9].
Among them, 4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phe-
nyl)-ethyl]-4,5-dihydro-pyrazol-1-yl}-benzoic acid (re-
ferred to as HBC) showed potent inhibitory activities
against the proliferation of several human cancer cells.
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Sejong University However, the mechanisms underlying how HBC inhibits
tumor cell growth are entirely unknown. Interestingly, itSeoul 143-747
Korea turned out that HBC did not inhibit the activity of CD13/
aminopeptidase N (APN), one of the direct binding tar-2 College of Pharmacy
Sungkyunkwan University gets of curcumin [10]. It has been speculated that HBC
may target a new protein critical for cell growth, ratherSuwon, Kyungkido 440-746
Korea than APN, in tumor cells. We thus attempted to isolate
the target protein of HBC using chemical genetics ap-
proaches. The affinity matrix-based protein purification
method requires high affinity of chemicals to their targetSummary
proteins [11]. However, HBC, which exhibits biological
activity around the 10 M range, is likely to have rela-HBC (4-{3,5-Bis-[2-(4-hydroxy-3-methoxy-phenyl)-ethyl]-
tively low affinity to its putative target protein, making it4,5-dihydro-pyrazol-1-yl}-benzoic acid) is a recently
unsuitable for affinity matrix-based protein purification.developed curcumin derivative which exhibits potent
Therefore, we conducted phage display biopanning,inhibitory activities against the proliferation of several
which is widely used for target identification of low affin-tumor cell lines. In the present study, we identified
ity ligands because the method can isolate proteins ex-Ca2/calmodulin (Ca2/CaM) as a direct target protein
isting at extremely low amounts in cells [3]. Using bio-of HBC using phage display biopanning. Ca2/CaM-
active biotinyl-HBC and phage display biopanningexpressing phages specifically bound to the immobi-
analysis, we presently isolated Ca2/calmodulin (Ca2/lized HBC, and the binding was Ca2 dependent. More-
CaM) as a direct target protein of HBC.over, flexible docking modeling demonstrated that
Ca2/CaM is a calcium binding protein which is impli-HBC is compatible with the binding cavity for a known
cated in a variety of cellular functions, including cellinhibitor, W7, in the C-terminal hydrophobic pocket of
growth and proliferation [12–14]. Ca2/CaM itself doesCa2/CaM. In biological systems, HBC induced pro-
not show any catalytic activity but regulates activitieslonged phosphorylation of ERK1/2 and activated
of a number of Ca2/CaM-dependent enzymes, such asp21WAF1 expression, resulting in the induction of G0/G1
myosin light chain kinase (MLCK) [15], CaM-kinases [16],cell cycle arrest in HCT15 colon cancer cells. These
phosphodiesterase [17], protein phosphatase [18], andresults suggest that HBC inhibits the cell cycle pro-
nitric oxide synthase [19]. Recently, evidence has showngression of colon cancer cells via antagonizing of Ca2/
that Ca2/CaM is implicated in cancers; e.g., an abnor-CaM functions.
mal expression of Ca2/CaM often occurs in certain tu-
mors [20], and specific antagonists of Ca2/CaM inhibit
Introduction the growth of a variety of tumor cells [21–23]. Thus,
Ca2/CaM has been recognized as a potential target for
Recent use of chemical genetics approaches makes cancer chemotherapy [24, 25]. The present study shows
possible the mining and the identification of specific for the first time that HBC is a new antagonist of Ca2/
target proteins of biologically active chemicals [1]. Affin- CaM and provides a critical clue for deciphering molecu-
ity matrix-based protein purification [2] and phage dis- lar mechanisms underlying the inhibition of tumor cell
play biopanning [3] have been developed as key solu- proliferation by HBC. The identification and validation
tions for this aim. These methods are based on the of Ca2/CaM as a functional target of HBC are described.
affinity selection of target proteins by immobilized bio-
active chemicals. Such approaches have been success-
fully employed to identify the specific target of a number Results
of bioactive chemicals, including FK506 [2], rapamycin
[4], trapoxin [5], radicicol [6], fumagillin [7], and taxol [8]. Antiproliferative Activity of HBC on Tumor Cells
Recently, a large number of chemicals that are biologi- Ongoing studies have focused on the identification of
cally interesting but with largely unknown mechanism new target proteins that play a critical role in cellular
have been isolated from natural products and chemical proliferation. HBC has been developed recently as a
libraries. Identification of targets of such chemicals can new curcumin derivative that inhibits the proliferation
provide tremendous benefits in functional genomics and of several tumor cell lines. Thus, we selected HBC as a
disease-related new drug development. chemical genetics probe for the identification of such
We previously developed several novel curcumin de- proteins. In the first step of the study, we investigated
the inhibitory activity of HBC on the proliferation of
HCT15 colon carcinoma cells, which showed the most*Correspondence: kwonhj@sejong.ac.kr
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Figure 1. Effect of HBC on the Proliferation of HCT15 Cells
(A) Time- and dose-responses of HBC on HCT15 cell proliferation are shown. The cell proliferation was measured by an MTT assay.
(B) Effect of HBC on the activity of APN. The assay procedure was described previously [10]. Curcumin and bestatin were used as positive
control compounds. All data represent mean  SE from three independent experiments.
sensitive response against the HBC treatment (data not identified as CaM-coding phages (about 70% of total
isolated phage clones). The translated sequence analy-shown). HBC dose- and time-dependently inhibited the
proliferation of HCT15 cells with an IC50 of 20 M (Figure sis demonstrated that the coding sequences of the
CaM-phages are 100% identical to C-terminal fragment1A). The proliferation of HCT15 cells was completely
inhibited by 40 M treatment with HBC. It was not cyto- (86 to 149 aa) of human CaM (Figure 2D). The other
five phage clones were identified as cytochrome b, far-toxic, because the population of HBC-treated cells at
the end of the assay was no less than the initial cell nesyltransferase, and three different unknown genes,
and were subsequently revealed as nonspecific binderspopulation. We previously demonstrated that hydrazi-
nocurcumin, a novel curcumin derivative, does not in- through phage binding assays (data not shown).
hibit aminopeptidase N activity [10]. In the present study,
HBC was also examined for effect on APN activity. The Ca2 Is Essentially Required
result shown in Figure 1B demonstrates that, like hy- for the Binding of HBC to CaM
drazinocurcumin, HBC does not inhibit APN activity at We next investigated the binding specificity of HBC to
any concentration used in this study. Therefore, we CaM-expressing phage (CaM-phage) using control bio-
speculated that there is a different cellular target of HBC tin and nonspecific phage encoding cytochrome b gene
rather than APN in mammalian cells that is critical for (Cyt. b-phage). As a result, CaM-phage specifically
cell growth. bound to the biotinyl-HBC, but not to control biotin im-
mobilized on streptavidin (Figure 3A). Moreover, CaM-
phage, but not Cyt. b-phage, was able to bind to theIdentification of Ca2/CaM as a Cellular
Binding Partner for HBC biotinyl-HBC immobilized on streptavidin. These data
indicate that CaM is a specific binding protein of HBC.To isolate the direct binding protein of HBC, we first
synthesized biotinyl-HBC as a molecular probe for tar- CaM is a major cellular Ca2 binding protein in which
conformational changes occur after the binding of Ca2get identification (Figure 2A). The biological activity of
the biotinyl-HBC was assessed via its inhibitory activity to its EF-hand motifs [26]. These conformational changes
of Ca2/CaM allow interaction with several Ca2/CaMagainst the proliferation of HCT15 cells. Biotinyl-HBC
inhibited the proliferation of the colon cancer cells with target proteins and its antagonists [27]. Thus, we investi-
gated whether Ca2 is required for the binding of CaMan IC50 of 42 M, which is 2-fold less potent than that
of the parental compound, HBC, but still indicates bio- to immobilized HBC. In the absence of exogenous Ca2,
CaM-phage can bind to immobilized HBC with high af-logical activity (Figure 2B). Biotinyl-HBC was then immo-
bilized onto streptavidin-coated wells, and T7 phages finity (Figure 3B), and exogenously added Ca2 slightly
increased the binding of CaM-phage to immobilizedencoding human cDNA libraries were used for affinity
selection of HBC binding protein. Increased phage parti- HBC. However, the addition of a Ca2 chelator, ethylene
glycol-bis(-aminoethylether)-tetraacetic acid (EGTA),cles were bound to HBC in proportion to each round of
biopanning, implying that specific HBC binding phages completely inhibited the binding of CaM-phage to immo-
bilized HBC (Figure 3C). To exclude the possibility thatwere enriched after progression of biopanning rounds
(Figure 2C). After the fourth round of biopanning, phage EGTA itself inhibits the binding between HBC and CaM,
the experiment was performed in the presence of EGTAparticles that specifically bound to HBC were isolated
using a plaque forming assay and then analyzed for DNA and an excess amount of Ca2. As shown in Figure 3D,
an excess amount of Ca2 (10 mM) fully reverses EGTAsequencing as described in the Experimental Proce-
dures. A total of 17 phage plaques were isolated for (2 mM)-induced disruption of the binding between HBC
and CaM. These results demonstrate that Ca2 is essen-sequence analysis, and the resulting data were then
subjected to sequence homology analysis using the tially required for the binding between HBC and CaM
and suggest that CaM expressed in the T7 phage mayBLAST search on the web (www.ncbi.nlm.nih.gov/
BLAST). Among 17 phage plaques isolated, 12 were be a Ca2 bound form.
Ca2/Calmodulin Is a Target of HBC
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Figure 2. Identification of HBC Binding Protein Using Phage Display Biopanning
(A) The structures of HBC, its molecular probe (biotinyl-HBC), and W7 are shown.
(B) Effects of HBC and biotinyl-HBC on the proliferation of HCT15 cells. The cells were treated with each compound for 72 hr, and an MTT
assay was performed to evaluate the biological activity of the compounds.
(C) Analysis of HBC binding phage particles eluted after each round of biopanning. “Wash” indicates nonspecific phages bound to biotinyl-
HBC immobilized on a streptavidin-coated well.
(D) Sequence homology between human CaM and the coding protein of HBC binding phage. The phage sequences were 100% identical to
the C-terminal (86–149) of human CaM.
Biochemical and Biophysical Validation of the of each N- and C-terminal domain [28]. These hydropho-
bic pockets are essential for Ca2/CaM to bind targetInteraction between HBC and Ca2/CaM
Three-dimensional structures of Ca2/CaM revealed that enzymes, peptides, and antagonists. Extensive studies
have shown that Ca2/CaM antagonists N-(6-amino-Ca2/CaM has two hydrophobic pockets on the surface
Figure 3. Effect of Ca2 and EGTA on the
Binding of HBC to Ca2/CaM
(A) The specificity of interaction between
HBC and CaM-expressing phage. Control bi-
otin and Cyt. b-phage were used as negative
controls for biotinyl-HBC and CaM-phage, re-
spectively. *p  0.0001 versus Cyt. b-phage.
(B) The effect of Ca2 on the binding of CaM-
phage to immobilized HBC is shown.
(C) The effect of EGTA on the binding of CaM-
phage to immobilized HBC is shown. *p 
0.0002 versus no EGTA control.
(D) Effect of an excess amount of Ca2 on
EGTA-induced disruption of the binding be-
tween HBC and CaM-phage. All data repre-




demonstrate that Ca2/CaM is a direct binding protein
of HBC.
Analysis of the Docking Model of HBC Bound
to C-Terminal Ca2/CaM Domain
A previous NMR structural study revealed that W7 binds
into the hydrophobic pocket of the C/N-terminal domain
of Ca2 bound CaM, which is the essential binding site
for target enzymes [30]. This study also suggested that
van der Waals interactions between the 5-chloro-naph-
thalene ring of W7 and aromatic/aliphatic amino acid
residues in the active site are crucial for competitive
inhibition of CaM-mediated enzyme activation. To ex-
amine a possible binding mode of HBC in the hydropho-
bic pocket of Ca2/CaM, a flexible docking study was
conducted using the FlexX program. The reference pro-
tein coordinate used for docking was taken from the
solution structure of the C-terminal domain of Ca2/CaM
in complex with W7 (PDB entry: 1MUX) [30]. Both S-
and R-form structures of HBC were prepared and then
docked into the W7 bound pocket. As shown in FigureFigure 4. Biochemical and Biophysical Analyses of the Binding be-
5A, docking results showed that R-HBC is not compati-tween HBC and Ca2/CaM
ble with the W7 binding cavity of Ca2/CaM, suggesting(A) Effects of several competitors on the binding of CaM C-phage
that R-HBC may not be an active form, while S-HBCto immobilized HBC. Control biotin was used as a negative control
in each competitor. All competitors were used at a concentration nicely fit into the hydrophobic pocket. The FlexX-docked
of 50 M. *p  0.0001, #p  0.001, and **p  0.0004 versus no pose of S-HBC is demonstrated in contrast to the NMR-
competitor control. Data represent mean  SE from three indepen- derived binding pose of W7 in Figure 5B. One vinylguaia-
dent experiments.
col arm of S-HBC anchors deep into the same pocket(B) BIAcore analysis of interaction between HBC and Ca2/CaM.
as is occupied by the chloronaphthalene ring of W7,Purified Ca2/CaM was immobilized on a CM5 sensor chip, and
and the phenolic hydroxy group forms a hydrogen bondvarious concentrations of HBC were loaded into the sensor cell.
Binding sensorgrams were obtained from the BIAcore evaluation with backbone amide of Met124. The remaining vinyl-
software. Kinetic parameters of ka, kd, KA, and KD are shown. guaiacol arm and benzoic acid-linked hydrazine moiety
of S-HBC cap the surface of protein. Especially, benzoic
acid-linked hydrazine group is fully superimposed overhexyl)-5-chloro-1-naphthalensulfonamide (W7) and tri-
the N-aminohexyl sulfonamido side chain of W7 on thefluoperazine (TFP) can bind to each hydrophobic pocket
surface of protein. Conclusively, the binding mode ofof N- and C-terminal domains of CaM in a Ca2-depen-
S-HBC generated by FlexX revealed that the structuredent manner and may inhibit the access of CaM-depen-
of the molecule is a good fit into the W7 binding cavitydent target enzymes [29, 30]. We next investigated
of Ca2/CaM, in which one vinylguaiacol arm and thewhether the interaction between HBC and Ca2/CaM is
benzoic acid-linked hydrazine moiety play a role as ainfluenced by several competitors, using phage display
capping group bigger than that of W7 and one vinylguai-binding analyses. A large molar excess of free HBC
acol group forms hydrophobic interaction with aminocompletely blocked the binding of CaM-phage to immo-
residues in the active site pocket. The present modelingbilized HBC (Figure 4A). W7 and TFP also significantly
study well elucidates the experimental result showinginhibited the interaction between HBC and CaM-phage.
that HBC has CaM binding capacity comparable to W7.The results from the competition assay suggest that
HBC has the highest binding affinity to CaM-phage
among three Ca2/CaM antagonists. However, another HBC Induces Sustained Phosphorylation
of ERK1/2cell cycle inhibitor, radicicol [31], did not interfere with
the interaction between two molecules. These data sug- We finally investigated the biological significance of the
binding of HBC to Ca2/CaM and attempted to validategest that HBC and two Ca2/CaM antagonists share a
common binding site within Ca2/CaM. We next exam- Ca2/CaM as a target protein of the compound for its
biological activity. Recent reports showed that extracel-ined the real-time interaction between HBC and intact
Ca2/CaM using surface plasmon resonance (BIAcore) lular signal-regulated kinase (ERK) 1/2 is a critical media-
tor of Ca2/CaM signaling [32–34]. Several antagonistsanalysis. Purified bovine brain CaM was immobilized on
a surface of a BIAcore sensor chip, and various concen- of Ca2/CaM induced sustained phosphorylation of
ERK1/2 and inhibited tumor cell proliferation. Thus, wetrations of HBC were injected into the sensor cells to
monitor the interaction between two molecules. Strong investigated the phosphorylation status of ERK1/2 in
tumor cells treated with HBC. Among eight cell linesbinding curves of HBC were observed in the sen-
sorgrams of BIAcore (Figure 4B). The kinetic parameters tested in this study, HCT15 turned out to express a
relatively high level of Ca2/CaM compared to othersof ka, kd, and KD were determined using BIAcore evalua-
tion software. As shown in Figure 4B, the apparent dis- and was selected as a model cell line for further study
(data not shown). In serum-starved HCT15 cells, HBCsociation constant (KD) of HBC binding to Ca2/CaM
was calculated as 8.11  106 M. These results clearly time dependently induced ERK1/2 phosphorylation (Fig-
Ca2/Calmodulin Is a Target of HBC
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Figure 5. Docking Model of HBC in Complex with the C-Terminal Ca2/CaM Domain
(A) FlexX-docked conformational ensemble of S-HBC versus R-HBC superimposed onto the NMR-structure of W7 (orange carbon) bound to
the C-terminal Ca2/CaM domain.
(B) The docking mode of the top-ranked conformer of S-HBC (gray carbon) obtained from FlexX. The Connolly molecular surface of the active
site is shown in purple, with the amino acid residues occupying the active site. Hydrogen atoms are not shown for clarity. The yellow dotted
line indicates hydrogen bonding interaction (d  1.244 A˚).
ure 6, upper panel). The phosphorylation of ERK1/2 was sequently inhibit cell cycle progression of tumor cells
via induction of G0/G1 cell cycle arrest [32, 33, 35]. Weretained up to 12 hr after treatment with HBC in serum-
starved HCT15 cells. The right panels in Figure 6 show thus examined the effect of HBC on p21WAF1 accumula-
tion in HCT15 cells. Western blot analysis revealed thatthe quantitative data for the phosphorylation pattern
of ERK1/2, which provides ratios of phosphorylated to HBC dose- and time dependently increased the level of
p21WAF1 expression (Figures 7A and 7B). W7 also acti-unphosphorylated ERK1/2. A high concentration of se-
rum (10%) also activated the phosphorylation of ERK1/2, vated p21WAF1 expression in HCT15 cells in a similar pat-
tern as that of HBC (Figure 7B). We next investigatedbut the activation was transient (Figure 6, middle panel).
In contrast, HBC treatment caused sustained phosphor- whether HBC inhibits the tumor cell proliferation by
causing arrest in a specific phase of the cell cycle.ylation of ERK1/2 in HCT15 cells in the presence of 10%
serum (Figure 6, lower panel). These data demonstrate HCT15 cells were synchronized by serum deprivation
for 24 hr, and then we added serum, allowing them tothat HBC binds to Ca2/CaM and influences the down-
stream signaling pathways of Ca2/CaM in the cells. reinitiate the cell cycle. The cell cycle distribution of
HCT15 cells was analyzed by flow cytometry. HBC dose
dependently inhibited cell cycle progression of HCT15HBC Inhibits Cell Cycle Progression of HCT15
cells (Figure 7C, upper panels). Accumulation of cells inCells by Inducing G0/G1 Arrest
G1 phase and the reduction in S phase demonstratedAccumulating evidence has shown that several antago-
nists of Ca2/CaM activate p21WAF1 expression and sub- that HBC induced G0/G1 cell cycle arrest. The time
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Figure 6. Analysis of ERK1/2 Phosphoryla-
tion in HCT15 Cells
Effects of HBC on the phosphorylation of
ERK1/2. (Upper panel) HCT15 cells were
starved in 1% FBS for 24 hr, and HBC was
treated for the indicated time points. Anti-
phospho-ERK1/2 antibody was used to de-
tect ERK1/2 phosphorylation. The levels of
ERK1/2 and tubulin were used as internal
controls. (Middle and lower panels) Effect of
10% serum only or 10% serum with HBC on
the phosphorylation of ERK1/2 is shown. Fig-
ures were selected as representative data
from three independent experiments. (Right
panels) Ratios of phosphorylated to unphos-
phorylated ERK1/2 were determined by densitometry. The phosphorylation ratio at each 0 hr (basal level phosphorylation) was normalized to
1 and used as a control in each experiment. Data are mean  SE from at least three independent experiments.
course analysis showed as well the induction of G0/G1 derivative and investigated its biological activity. The
cell cycle arrest by HBC (Figure 7C, lower panels). W7 present study focuses on the identification of a putative
also induced G0/G1 cell cycle arrest in HCT15 cells (data target protein of HBC in mammalian cells, using a chemi-
not shown). These results clearly demonstrate that the cal genetics approach. To identify the cellular target
antiproliferative activity of HBC against HCT15 cells protein of HBC, we tried to isolate the direct binding
happens, at least in part, through the antagonization of protein of the compound from genomic libraries using
the Ca2/CaM function in colorectal carcinoma cells. phage display biopanning. The results from in vitro and
cell-based assays demonstrate that Ca2/CaM is a puta-
tive target protein of HBC.Discussion
Ca2/CaM consists of N- and C-terminal domains
which contain two EF-hand Ca2 binding motifs in eachChemical genetics is an emerging research engine to
domain [26]. The three-dimensional structures of Ca2/study unidentified protein functions using biologically
CaM revealed that Ca2 binding to apo-CaM causesactive small molecules. Several small molecules which
conformational changes from the closed to the openare biologically interesting but are largely unknown in
form [36, 37]. This conformational change can generatetheir action mechanisms have been attractive targets
a hydrophobic pocket on the surface of each domainfor chemical genetics studies [2, 4–7]. A large number
and provides binding sites for Ca2/CaM target enzymesof such small molecules have been isolated from natural
as well as several antagonists [27–30]. Well-known Ca2/products and chemical libraries so far. Identification of
CaM antagonists TFP and W7 can bind to both N- andintracellular target proteins of these biologically interest-
C-terminal hydrophobic pockets [29, 30]. In our study,ing small molecules will have a tremendous impact on
HBC specifically binds to Ca2/CaM-expressing phagesboth functional genomics and drug development.
We previously developed HBC as a novel curcumin in a Ca2-dependent manner. Moreover, TFP and W7
Figure 7. Analyses of p21WAF1 Expression and
Cell Cycle Progression of HCT15 Cells
(A) Dose response of HBC on the expression
of p21WAF1. The level of tubulin was used as
an internal control for normalization.
(B) Time response of HBC on the expression
of p21WAF1. W7 was used as a positive control
compound.
(C) Dose- (upper panels) and time (lower pan-
els) responses of HBC on the cell cycle distri-
bution of HCT15 cells are shown. Figures
were selected as representative data from
three independent experiments.
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specifically block the binding of HBC to Ca2/CaM, sug- play biopanning analysis to identify the cellular target
protein of HBC from genome-wide human cDNA librar-gesting that HBC may bind to the hydrophobic pocket
of each domain of Ca2/CaM. Flexible docking analysis ies. As a result, we isolated a major binding protein
of HBC from the phage libraries and subsequentlyof the binding of HBC to the C-terminal hydrophobic
pocket of Ca2/CaM further supported this possibility. identified Ca2/CaM as a putative target protein of
HBC. Direct interaction between HBC and Ca2/CaMIn the docking model, S-HBC, but not R-HBC, nicely fits
into the W7 binding cavity in the C-terminal hydrophobic was confirmed using both phage display binding assay
and surface plasmon resonance analysis. Flexiblepocket of Ca2/CaM. Three-dimensional structure anal-
ysis of the binding between two molecules will help to docking modeling of the binding between HBC and
Ca2/CaM suggests a possible binding mode of thedecipher the exact binding mode of HBC to Ca2/CaM.
The interaction between HBC and full-length Ca2/CaM new Ca2/CaM antagonist. In biological systems, HBC
induces sustained phosphorylation of ERK1/2 and ac-was confirmed by surface plasmon resonance analysis.
The apparent KD value of the binding appears at 8.11 tivates p21WAF1 expression, resulting in the suppression
of the cell cycle progression of HCT15 colon cancerM, which is similar to that of TFP and W-7 (ranging
from 1 to 8 M for TFP and 11 M for W-7) [38–40]. cells. These biological activities of HBC are similar to
those of other Ca2/CaM antagonists, suggesting thatThese data demonstrate that HBC directly binds to Ca2/
CaM with a relatively high affinity. Ca2/CaM is a biologically relevant target of HBC. The
present study demonstrates that HBC is a new Ca2/Ca2/CaM is a multifunctional protein which binds to
a variety of cellular proteins and regulates their activities. CaM antagonist with a unique structure and offers a
lead compound for the development of more potentRecently, several antagonists of Ca2/CaM were re-
ported to activate ERK1/2 and then regulate down- Ca2/CaM antagonists. Moreover, this study support
the idea that Ca2/CaM is an emerging target for antitu-stream target gene expression [32–34]. They include
p21WAF1 [32] and Egr-1 [34]. These studies demonstrated mor drug development.
that ERK1/2 is a critical mediator for Ca2/CaM signaling
Experimental Proceduresin cell cycle regulation. ERK1/2 is a serine/threonine
protein kinase which is rapidly activated by extracellular
Materialsmitogenic signals and contributes to cellular prolifera- All docking experiments were performed with Sybyl (version 6.9,
tion [41, 42]. However, sustained phosphorylation of Tripos Inc., St. Louis, MO) on an SGI-Octane 2 workstation with a
ERK1/2 has been reported to suppress cell cycle pro- single 475 MHz processor and 128 MB main memory.
gression by the induction of p21WAF1 and in turn inhibit
Cell Culture and Growth Assaycancerous growth of tumor cells [43, 44]. Thus, the
HCT15 colon carcinoma cells were grown in Dulbecco’s modifiedstrength and duration of ERK1/2 phosphorylation seem
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serumto be a critical criteria for its role in the tumor promoting
(FBS). The cells were maintained in a humidified incubator supple-
or suppressive function. Our data demonstrate that HBC mented with 5% CO2. The proliferation of the tumor cells was mea-
induces sustained ERK1/2 phosphorylation in HCT15 sured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
cells in the presence of both low and high concentra- bromide (MTT) assay. Cells were seeded in 96-well plates (5  103
cells/well) and incubated for 24 hr. The cells were treated with eithertions of serum. Moreover, HBC highly increased the
HBC or biotinyl-HBC at various concentrations and time conditions.expression of p21WAF1 in HCT15 cells and inhibited the
At the end of the assay, MTT (50 g/ml) was added to each well,cell cycle progression of the cells by inducing G0/G1 and the incubation was continued for 4 hr. MTT-formazan in each
arrest. These data suggest that HBC inhibits cell cycle well was dissolved in 150 l DMSO, and the absorbance was read
progression of the colon cancer cells via ERK1/2/p21WAF1 at 540 nm using a microplate reader (Bio-Tek Instrument Inc., Winoo-
pathways and demonstrate that Ca2/CaM is a biologi- ski, VT).
cally relevant target of HBC in mammalian cells.
Synthesis of Biotinyl-HBCRecent strategies for cancer chemotherapy have been
To a stirred solution of HBC (10 mg, 0.021 mmol) and EZ-Link biotin-focused on the development of new cancer targets that
PEO-amine (9.4 mg, 0.026 mmol, Pierce Biotechnology Inc., Rock-are “single target with multiple effects” [45]. Ca2/CaM
ford, IL) in DMF (3 ml) was added EDC (5.0 mg, 0.026 mmol) and
possesses a high potential for being a promising cancer HOBt (3.5 mg, 0.026 mmol) at 0	C. The reaction mixture was allowed
target, because (1) abnormal expression of Ca2/CaM to warm to room temperature and stirred overnight. Brine (6 ml) was
often occurs in several cancer types [20, 24, 25], and added to the reaction mixture, and the resulting aqueous solution
was extracted with EtOAc (5 ml  3). The combined organic layer(2) Ca2/CaM is involved in a number of cellular signaling
was washed with 1 N HCl (4 ml) and brine (4 ml), dried over MgSO4,pathways via regulation of the activities of a variety of
filtered, and concentrated in vacuo. The crude product was purifiedits client proteins [12–19]. Development of more potent
by flash column chromatography (CH2Cl2:MeOH  10: 1) to affordderivatives of HBC using structure-activity relationship pure biotin linked HBC compound in 85% yield. MALDI-MS: calcu-
analysis, and in vivo efficacy validation of such com- lated (M  843.0); found (M-H) 841.9.
pounds, will be our next challenge for new drug develop-
ment targeting Ca2/CaM in cancer. Phage Display Biopanning
Biotinyl-HBC diluted in Tris-buffered saline (TBS [pH 7.5]) was immo-
bilized to a streptavidin-coated well (Pierce Biotechnology, Inc.) at
a concentration of 5 M. T7 phage particles encoding human cDNASignificance
libraries from liver tumor, normal liver, Alzheimer’s brain, normal
brain, and normal stomach tissues (Novagen, Madison, WI) were
HBC is a synthetic benzoic acid derivative of curcumin, diluted in TBS (6  109 pfu/ml) and added to the HBC-immobilized
which shows different biological activities from the wells. After incubation for 1 hr at room temperature with gentle
shaking, the well plate was washed ten times with TBS, and boundparental compound curcumin. We utilized phage dis-
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phage particles were eluted with 100 M HBC diluted in TBS for The cell lysates were separated by 10% SDS-PAGE, followed by
transfer to PVDF membranes (Milipore, Bedford, MA) using standard1 hr. The eluted phage particles were amplified after infection into
E. coli strain BLT5615, and the amplified phage particles were used electroblotting procedures [46]. Blots were then blocked and immu-
nolabeled overnight at 4	C with primary antibodies, including anti-for second round biopanning. After fourth round biopanning, eluted
phages were infected in to BLT5615 grown on an LB agar plate p21WAF1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phos-
phoERK1/2 (Cell Signaling Technology, Inc., Beverly, MA), anti-ERK1/2supplemented with 50 g/ml ampicillin. The plaques formed on the
agar plate were isolated, and the DNAs from the isolated plaques (Cell Signaling Technology, Inc.), and anti-tubulin (Upstate Biotech-
nology, Lake Placid, NY) antibodies. Immunolabeling was detectedwere sequenced with the PRISM Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA). by an enhanced chemiluminescence (ECL) kit (Amersham Life Sci-
ence, Inc. Buckinghamshire, UK) according to the manufacturer’s
instructions.Surface Plasmon Resonance Analysis
Purified bovine brain CaM (Calbiochem, San Diego, CA) was cova-
Cell Cycle Analysis by Flow Cytometrylently linked to a CM5 sensor chip with the surface thiol coupling
HCT15 cells were seeded in 6-well plates (105 cells/well) and incu-method according to the manufacturer’s instructions (BIAcore AB,
bated for 24 hr. The cells were starved for 24 hr with serum-freeUppsala, Sweden). CaM was modified to a thiol-containing protein
DMEM. After synchronization, the cells were treated with or withoutby incubation with a molar excess of 2-(2-pyridinyldithio)ethanea-
HBC, and the incubation was continued for 24 hr in the presencemine (PDEA), followed by 0.4 M N-ethyl-N
-(3-diethylaminopropyl)-
of 10% serum. Then, the cells were harvested with trypsinization,carbodiimide (EDC) in water for 1 hr on ice. Unreacted reagents
fixed, and permeabilized in the presence of 70% ethanol. The cellswere removed by an Amicon microconcentrator (Millipore, Bedford,
were centrifuged and resuspended in phosphate-buffered salineMA). The surface matrix of the CM5 sensor chip was activated by
(PBS [pH 7.4]). To reduce background staining, RNase (80 g/ml)a 2 min injection of an aqueous solution of 0.2 M EDC and 50 mM
was added, followed by specific DNA-staining using propidium io-N-hydroxysuccinimide (NHS), and subsequently by a 3 min injection
dide (50 g/ml). The DNA histograms were determined using a Bec-of 40 mM cystamine dihydrochloride solution. The reduction of sur-
ton-Dickinson FACS Vantage flow cytometer system (Becton-Dick-face thiol was achieved by a 3 min injection of 0.1 M dithiothreitol
inson, San Jose, CA), and the cell cycle distribution was analyzed(DTT). Thiol-modified CaM (200 g/ml) diluted in sodium acetate
using Cell Quest software version 3.2 (Becton-Dickinson).buffer (pH 4.0) was injected into the sensor cells for 7 min. All
coupling reactions were performed at a flow rate of 5 l/min. Resid-
ual cystamine molecules on the surface of the sensor chip were Statistical Analysis
inactivated by injection of 20 mM PDEA-1 M NaCl solution for 4 min. Results are expressed as the mean standard error (SE). Student’s
For the binding analysis, compounds in the running buffer (10 mM t test was used to determine statistical significance between control
HEPES [pH 7.4], 150 mM NaCl, and 3 mM EDTA) containing 5% and test groups. A p value of 0.05 was considered statistically
DMSO were injected at a flow rate of 30 l/min. Association and significant.
dissociation curves were obtained on a BIAcore 2000. The surface
of the sensor chip was regenerated by injection of 10 l of the Acknowledgments
regeneration buffer (10 mM NaCl and 0.1 mM NaOH). The SPR
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